A prospective study of circulating adipokine levels and risk of multiple myeloma
Mené sur 174 patients atteints d'un myélome multiple et sur 348 témoins, cet essai prospectif évalue l'association entre les niveaux d'adipokines circulantes (leptine, adiponectine) et le risque de développer la maladie
It has been hypothesized that the observed excess risk of multiple myeloma (MM) among obese individuals could be due to altered circulating levels of adipokines, polypeptide hormones with pro- and anti-inflammatory properties secreted by adipose tissue. We investigated whether circulating levels of leptin, total adiponectin, and high-molecular-weight (HMW) adiponectin are associated with subsequent MM risk among 174 MM patients and 348 controls within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Inverse associations with MM were observed for total adiponectin (highest quartile vs. lowest: odds ratio=0.49, 95% confidence interval=0.26-0.93, Ptrend=0.03) and HMW adiponectin (0.44, 0.23-0.85, Ptrend=0.01). These associations remained after restricting to MM patients diagnosed approximately eight years or more after blood collection. Leptin levels were not associated with MM risk. The results of this study, to our knowledge the first prospective investigation of circulating adipokines and MM, suggest that adiponectin may play an important role in obesity-related myelomagenesis.